Aortic Center—Long Island | NYU Langone Health
Cardiac and vascular surgeons at NYU Langone’s Aortic Center —Long Island provide advanced treatment for aortic aneurysm.
Aortic Center—Long Island Doctors | NYU Langone Health
Find a doctor at the Aortic Center—Long Island at NYU Langone.
Aortic Center—Manhattan | NYU Langone Health
Cardiac and vascular surgeons at NYU Langone’s Aortic Center—Manhattan provide advanced treatments to support your aortic health.
Aortic Center—Manhattan Doctors | NYU Langone Health
Find a doctor at the Aortic Center—Manhattan at NYU Langone.
Aortic Dissection | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and vascular surgeons are highly trained in diagnosing and treating aortic dissections.
Aortic Valve Disease | NYU Langone Health
NYU Langone cardiologists, cardiothoracic surgeons, and interventional cardiologists are highly trained in managing aortic valve disease.
Aortoiliac Occlusive Disease | NYU Langone Health
NYU Langone vascular specialists manage aortoiliac occlusive disease, which limits blood flow to the pelvis and legs.
APEC1621SC: NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL
The Pediatric MATCH (Molecular Analysis for Therapy Choice) study, (referred to as Pediatric MATCH in the remainder of this document), will match targeted agents with specific molecular changes identified using genomic sequencing technologies in refractory/recurrent tumors from children and adolescents with cancer. Pediatric MATCH will build upon experience from the adult NCI MATCH clinical trial. PediatricMATCH will be a national trial under a single IND and will be led by NCI and the Children’s Oncology Group (COG), a member of the NCI National Clinical Trial Network (NCTN). Pediatric MATCH will employ an analytically validated next-generation sequencing targeted assay of more than 4,000 different mutations (SNVs, indels, copy number alterations, and gene fusions) across more than 140 genes. This assay will be coupled to a computer algorithm that uses pre-existing definitions and prioritization of target-agent pairs to assign patients by actionable mutation results to a targeted treatment.The primary endpoint for Pediatric MATCH will be objective response rate. The study will use a trial design with the flexibility to open and close arms. The study drugs included in this trial will include agents that have at least an adult recommended phase 2 dose and that have shown some activity against tumors with a particular genetic alteration(s). Patients with recurrent or refractory tumors enrolled on study willhave a tumor sample available for molecular characterization, and those with molecular variants addressed by treatments included in the trial will be offered treatment on Pediatric MATCH.
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Apps | NYU Langone Health
NYU Langone Health has launched several mobile apps to improve access to patient care and to conduct research studies.